# Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

> **NCT00796666** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 131 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension
- Pulmonary Hypertension

## Interventions

- **DRUG:** Sitaxsentan
- **DRUG:** Sitaxsentan and Sildenafil

## Key facts

- **NCT ID:** NCT00796666
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 131 (ACTUAL)
- **Why stopped:** Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.
- **Last updated:** 2015-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796666, "Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00796666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*